SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Magainin Pharm (MAGN) -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (184)6/18/1999 7:20:00 PM
From: BulbaMan  Read Replies (1) | Respond to of 233
 
FDA approval of MAGN's Locilex may be helped by Pfizer's Trovan troubles. Trovan was being prescribed for diabetic foot ulcers and, given the recent warning on its safety problems, the FDA may have more incentive to provide the topical alternative of Locilex.
IMHO, at $1.75, MAGN's stock price assumes zero probability of Locilex approval. However, I think the chances are even greater than the 10-15% posted earlier.



To: Mike McFarland who wrote (184)7/20/1999 4:08:00 PM
From: Michael Cash  Read Replies (1) | Respond to of 233
 
How much more concentrated is the squalamine being tested by MAGN than the naturally-occuring squalene found in shark liver oil? Would it be theoretically possible to ingest enough shark liver oil to achieve some benefit for a cancer patient? If so, how much would be required?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News